Skip NavigationSkip to Content
Return Return to Search Results

Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care

  1. Author:
    Dong, Haoru
    Shu, Xinhua
    Xu, Qiang
    Zhu, Chen
    Kaufmann, Andreas M.
    Zheng,Zhi-Ming
    Albers, Andreas E.
    Qian, Xu

  2. Author Address

    Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp,Dept Clin Lab,Canc Hosp, Hangzhou 310022, Peoples R China.Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp,Zhejiang Canc Hosp, Hangzhou 310022, Peoples R China.Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Canc Prevent,Canc Hosp,Zhejiang Canc Hosp, Hangzhou 310022, Peoples R China.Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Clin Gynecol,Berlin Inst Hlth, D-12203 Berlin, Germany.NCI, Tumor Virus RNA Biol Sect, HIV Dynam & Replicat Program, NIH, Frederick, MD 21702 USA.Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Berlin Inst Hlth,Dept Otolaryngol Head & Neck Sur, D-13353 Berlin, Germany.
    1. Year: 2021
    2. Date: Jun 21
    3. Epub Date: 2021 06 21
  2. Journal: Virologica Sinica
  3. SPRINGER,
  5. Type of Article: Review
  6. ISSN: 1674-0769
  1. Abstract:

    Human papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%-80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s12250-021-00413-8
  3. PMID: 34152564
  4. View record in Web of Science®
  5. WOS: 000663976100002

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel